Estimaciones de analistas de Wall Street para Seres Therapeutics, Inc. (MCRB): precio objetivo de consenso, recomendaciones de compra/mantener/venta y previsiones de ingresos, BPA y EBITDA para los próximos ejercicios.
Consenso de analistas
| Compra fuerte | 0 |
| Compra | 11 |
| Mantener | 3 |
| Venta | 4 |
| Venta fuerte | 0 |
| Analistas totales | 18 |
| Calificación media (1-5) | 0.39 |
Sorpresas de Resultados Recientes
| Fecha | BPA Real | BPA Estimado | vs Est. |
|---|---|---|---|
| 2026-11-04 | $-1.00 | ||
| 2026-08-05 | $0.47 | $-2.18 | +121.6% |
| 2026-05-05 | $-2.08 | $-1.88 | -10.6% |
| 2026-03-12 | $-1.78 | $-2.39 | +25.5% |
| 2025-11-05 | $0.94 | $0.05 | +1780.0% |
| 2025-08-06 | $-2.27 | $-2.72 | +16.5% |
| 2025-05-07 | $-3.75 | $-0.67 | -459.7% |
| 2025-03-13 | $-1.80 | $-0.17 | -958.8% |
Ratios de valoración
| Precio / Valor contable | 1.32 |
| EV / EBITDA | -2.17 |
| Rentabilidad por dividendo | 0.00% |
Cuenta de Resultados (10 años)
| Año | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Ingresos | $21.8M | $32.1M | $28.3M | $34.5M | $33.2M | $144.9M | 0 | 0 | 0 | $789000 |
| Coste de Ventas | $82.0M | $89.5M | $96.0M | 0 | $90.6M | 0 | 0 | $19.3M | $3.5M | $4.1M |
| Beneficio Bruto | -$60.2M | -$57.4M | -$67.7M | $34.5M | -$57.4M | $144.9M | 0 | -$19.3M | -$3.5M | -$3.3M |
| I+D | $82.0M | $89.5M | $96.0M | $80.1M | $90.6M | $141.9M | $109.7M | $117.6M | $64.6M | $49.1M |
| Generales y Administrativos | $32.6M | $34.0M | $32.6M | $24.7M | $30.8M | $69.3M | $70.3M | $77.5M | $53.2M | $39.2M |
| Gastos Operativos | $114.6M | $123.5M | $128.6M | $106.4M | $30.8M | $209.4M | $179.9M | $175.8M | $117.8M | $90.6M |
| Beneficio Operativo | -$92.8M | -$91.4M | -$100.3M | -$71.9M | -$88.1M | -$64.5M | -$179.9M | -$195.1M | -$121.3M | -$94.0M |
| EBITDA | -$88.6M | -$82.1M | -$91.1M | -$62.2M | -$77.3M | -$56.7M | -$170.9M | -$181.4M | -$120.3M | $9.8M |
| Gastos por Intereses | $969000 | $1.6M | $1.2M | $502000 | $2.9M | $2.9M | $6.0M | $13.2M | 0 | 0 |
| Beneficio Antes de Impuestos | -$91.6M | -$89.4M | -$98.9M | -$70.3M | -$89.1M | -$65.6M | -$183.6M | -$190.1M | -$125.8M | $5.7M |
| Impuestos | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Beneficio Neto | -$91.6M | -$89.4M | -$98.9M | -$70.3M | -$89.1M | -$65.6M | -$250.2M | -$113.7M | -$146.6M | $5.7M |
| BPA | $-46.00 | $-44.19 | $-48.57 | $-24.81 | $-22.34 | $-14.30 | $-46.29 | $-17.77 | $-18.86 | $0.64 |
| BPA Diluido | $-46.00 | $-44.19 | $-48.57 | $-24.81 | $-22.34 | $-14.30 | $-46.29 | $-17.77 | $-18.86 | $0.64 |
| Acciones en Circulación (Diluidas) | $2.0M | $2.0M | $2.0M | $2.8M | $4.0M | $4.6M | $5.4M | $6.4M | $7.8M | $8.9M |
Precio
| Precio | $4.21 |
| Capitalización | $41M |
| Bolsa | NASDAQ |
| País | US |
Empresas relacionadas: ABOS · ACTU · APLT · CGTX · HURA · INO · IRD
Explorar sector: Healthcare · Biotechnology
Más secciones de MCRB: Resumen · Financieros · Valoración · Estadísticas · Técnico · Propiedad · Noticias · Eventos
Descubre más: Radar — señales de acciones infravaloradas · Academia de Inversión — aprende a analizar acciones